Studies have demonstrated that combining EphA2-targeted therapies with inhibitors of the DNA damage response, such as Wee1 kinase inhibitors, can enhance therapeutic efficacy by inducing apoptosis and reducing tumor cell viability (44). The gene discussed is EPHA2; the disease is neoplasm.